Abstract:
People infected by severe acute respiratory coronavirus 2 (SARS-CoV-2) risk the development of not only acute coronavirus- disease-2019 (COVID-19) – the signs and symptoms of which range from none to severe illness that requires intensive treatment – but also long COVID (i.e., chronic COVID), a cyclical, progressive, multiphasic illness characterized by myriad debilitating conditions that persist long term. In some patients, those sequelae result in psychiatric disorders that can lead to suicide or other forms of self-harm, incidences of which have increased exponentially since before the COVID pandemic. It has been suggested that long COVID develops in an estimated 10% to 35% of people diagnosed as having COVID-19.
Because the success of therapy for either form of COVID can be complicated by each patient’s pharmacogenomic profile, personal treatment preferences, medical needs, and/or dosing requirements, we have found that in some people so afflicted, manufactured medications are ineffective or intolerable, and that for those individuals, a customized compound often provides relief and promotes recovery. The primary focus of this article is long COVID. The pathogenesis of that disease is reviewed, therapies for the signs and symptoms it engenders are examined, and 2 compounded formulations effective in treating both acute and chronic COVID-19 are presented.
Source: Riepl M, Kaiser J. Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID. Int J Pharm Compd. 2023 Jul-Aug;27(4):284-293. PMID: 37595172. https://pubmed.ncbi.nlm.nih.gov/37595172/